Vectura Group PLC (LON:VEC) announced a dividend on Tuesday, September 10th, Upcoming.Co.Uk reports. Shareholders of record on Monday, October 14th will be paid a dividend of GBX 6 ($0.08) per share on Friday, October 25th. The ex-dividend date is Monday, October 14th. The official announcement can be seen at this link.
Shares of LON:VEC traded up GBX 1.30 ($0.02) during trading on Wednesday, hitting GBX 81 ($1.06). 750,806 shares of the company’s stock traded hands, compared to its average volume of 4,610,000. The company has a current ratio of 2.35, a quick ratio of 1.90 and a debt-to-equity ratio of 0.81. The company has a 50-day moving average price of GBX 78.95 and a 200-day moving average price of GBX 78.08. Vectura Group has a 52 week low of GBX 65.85 ($0.86) and a 52 week high of GBX 90.15 ($1.18). The company has a market cap of $543.04 million and a price-to-earnings ratio of -6.14.
A number of analysts recently issued reports on the company. Morgan Stanley reissued a “buy” rating and set a GBX 160 ($2.09) target price on shares of Vectura Group in a research note on Friday, May 24th. Citigroup reaffirmed a “buy” rating on shares of Vectura Group in a research note on Wednesday. Numis Securities reiterated a “buy” rating on shares of Vectura Group in a report on Friday, May 24th. Peel Hunt reissued a “hold” rating on shares of Vectura Group in a research report on Monday. Finally, Shore Capital restated a “hold” rating on shares of Vectura Group in a report on Tuesday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Vectura Group has an average rating of “Buy” and a consensus target price of GBX 125.40 ($1.64).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.